EPHEDRINE OTC STATUS OPPOSED BY FDA ADVISORY COMMITTEE
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE OTC STATUS OPPOSED BY FDA ADVISORY COMMITTEE on Nov. 14 due to concerns about the misuse and abuse of ephedrine- containing OTCs and herbal products as stimulants, diet pills and muscle enhancers. Summarizing the views expressed by FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committee, FDA Office of OTC Drug Evaluation Director Michael Weintraub, MD, noted that the consensus was "pretty clear" that ephedrine be discontinued as an OTC drug ingredient.